Fresh analysis indicates that people who discontinue new GLP-1 drugs like Wegovy and Mounjaro tend to recover lost weight much more quickly than those who halt conventional diet and exercise regimens.
Published data in a major medical journal points out that while obese people frequently drop substantial amounts of their total mass while undergoing treatment, the mass returns at an estimated rate of 0.8 kg per month after stopping.
"Individuals using these medications must be aware of the risk of quick rebound weight gain when the therapy concludes," warns lead investigator Dr. Susan Jebb.
That rate of regain implies a return to original weight in about one and a half years.
Analyzing Approaches
The analysis, which looked at dozens of trials involving over 9,000 of participants, contrasted the effects of the injectable medications with older methods.
Scientists note that people who shed pounds through lifestyle changes alone generally experience a less rapid creep back—around 100 grams monthly—once they finish.
Explaining the Fast Rebound
Doctors propose the way of the injections accounts for the amplified regain.
GLP-1 drugs mimic a body's own chemical called GLP-1, which controls feelings of fullness.
"Sustained high doses of the hormone levels far above than normal could lead to the body to produce less of its endogenous GLP-1, and may also lessen sensitivity to its effects," said Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this GLP-1 'fix' results in appetite is unsuppressed, making excessive eating far more likely."
A Chronic Disease?
Health authorities recommend the jabs for people with obesity-related health risks, alongside prescribed diet and exercise modifications.
Many experts argue that, due to the likelihood of weight regain, the therapy should be considered life-long.
This opinion is reinforced by drug manufacturers, who say that the results "underscore the chronic nature of obesity," comparing it to managing conditions like high blood pressure.
Patient Testimonies
People who have discontinued the medication explain a intense return of hunger.
"It felt as if a trigger activating and you become ravenous," recalled one woman.
The struggle is exacerbated if users have not adopted permanent lifestyle or habit modifications during treatment.
Widespread Use
Survey data suggest that millions of people in the UK have tried these injections in the past year, with desire being substantial.
- Use is higher among females than men.
- The middle-aged age group shows the highest level of interest.
- Many access the drugs through private healthcare rather than public health services.
In conclusion, researchers emphasize that while GLP-1 drugs are effective agents for weight loss, they are not a permanent cure and maintained weight loss relies on ongoing behavioural changes.
